(Q51825111)

13 April 2018

title

DNA fusion vaccine designs to induce tumor-lytic CD8+ T-cell attack via the immunodominant cysteine-containing epitope of NY-ESO 1. (English)

1 reference

13 April 2018

author

Freda K. Stevenson

7

1 reference

13 April 2018

Mary Collins

4

object named as

Mary Collins

1 reference

13 April 2018

David Escors

object named as

David Escors

3

0 references

author name string

Juan Campos-Perez

1

1 reference

13 April 2018

Jason Rice

2

1 reference

13 April 2018

Alex Paterson

5

1 reference

13 April 2018

Natalia Savelyeva

6

1 reference

13 April 2018

language of work or name

English

0 references

publication date

11 April 2013

1 reference

13 April 2018

International Journal of Cancer

published in

1 reference

13 April 2018

volume

133

1 reference

13 April 2018

issue

6

1 reference

13 April 2018

page(s)

1400-1407

1 reference

13 April 2018

Cancer/testis (CT) antigens: potential targets for immunotherapy

cites work

1 reference

NY-ESO-1: review of an immunogenic tumor antigen

21 January 2018

1 reference

Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.

21 January 2018

1 reference

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes

21 January 2018

1 reference

The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients

21 January 2018

1 reference

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

21 January 2018

1 reference

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

21 January 2018

1 reference

Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-ex

21 January 2018

1 reference

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

21 January 2018

1 reference

Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients

21 January 2018

1 reference

Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants

21 January 2018

1 reference

Functional and structural characteristics of NY-ESO-1-related HLA A2-restricted epitopes and the design of a novel immunogenic analogue

21 January 2018

1 reference

Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.

21 January 2018

1 reference

Using modified antigenic sequences to develop cancer vaccines: are we losing the focus?

21 January 2018

1 reference

DNA fusion gene vaccination mobilizes effective anti-leukemic cytotoxic T lymphocytes from a tolerized repertoire

21 January 2018

1 reference

DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time

21 January 2018

1 reference

LAGE-1, a new gene with tumor specificity

21 January 2018

1 reference

DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance

21 January 2018

1 reference

HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice

21 January 2018

1 reference

Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides.

21 January 2018

1 reference

DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized repertoire

21 January 2018

1 reference

Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response

21 January 2018

1 reference

Targeting dendritic cell signaling to regulate the response to immunization

21 January 2018

1 reference

Growth factors improve gene expression after lentiviral transduction in human adult and fetal hepatocytes

21 January 2018

1 reference

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

21 January 2018

1 reference

CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients

21 January 2018

1 reference

Constraints within major histocompatibility complex class I restricted peptides: Presentation and consequences for T-cell recognition

21 January 2018

1 reference

DNA vaccines: precision tools for activating effective immunity against cancer.

21 January 2018

1 reference

NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells.

21 January 2018

1 reference

CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes

21 January 2018

1 reference

Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen

21 January 2018

1 reference

DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer

21 January 2018

1 reference

Electropermeabilization of skeletal muscle enhances gene transfer in vivo

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.28156

1 reference

13 April 2018

1 reference

13 April 2018